Stem cell trial for knee osteoarthritis underway


By Lauren Davis
Monday, 10 August, 2015

Stem cell trial for knee osteoarthritis underway

Regeneus (ASX:RGS) shares jumped over 20% today as the regenerative medicine company announced the first patient to be treated by Progenza, its mesenchymal stem cell (MSC) therapy treatment for knee osteoarthritis.

The patient was the first of 20 participants in the STEP (Safety, Tolerability and Efficacy of Progenza) clinical trial. The primary objective of the trial is to evaluate the safety and tolerability of Progenza, while the secondary objectives are to investigate the effect of the product over 12 months.

The stem cells in Progenza are sourced from adipose tissue, which is readily available and can be sourced in large initial quantities — the company has already demonstrated the capacity to produce over 10 million therapeutic doses of Progenza from a single donor. When Progenza cells are injected into a damaged joint or tissue, the MSCs have the potential to reduce pain and inflammation and slow the progression of the disease.

As a review of the sentinel patient’s safety data by the STEP safety oversight committee identified no safety concerns, enrolment in trial is now open to the remainder of the first cohort of 10 patients. A second and final cohort will receive a higher dose of cells.

Regeneus (ASX:RGS) shares peaked at $0.16 — a gain of 23.08% — at around 12.30 pm on Monday. They had dropped slightly to $0.155 as of around 1.30 pm.

Image caption: ©freeimages.com/profile/adamci

Related News

Newly discovered 'giant' bacterium visible to the naked eye

Thiomargarita magnifica is larger than all other known giant bacteria by ~50-fold, and...

Uterus transplant safe and effective at combating infertility

Transplanting a uterus is an effective and safe method to remedy infertility when a functioning...

Skiers at elevated risk of skin cancer, dermatologist says

Australia's lack of pollution significantly increases exposure to UV — particularly at...


  • All content Copyright © 2022 Westwick-Farrow Pty Ltd